Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Renal and Urologic Disorders » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Issues in Dialysis
02.Trends in Prostate Cancer Research (In: Horizons in Cancer Research, Volume 7)
03.Handbook of Common Problems in Clinical Nephrology
04.Endoscopic Vaporization in Lower Urinary Tract Pathology – From Monopolar to Plasma
05.Biomarkers in Renal Disease
06.Neutrophil Gelatinase-Associated Lipocalin: from Laboratory to Clinical Utility
07.Vascular Access for the General Nephrologist
08.Issues in Dialysis
09.Nephrology - Dialysis - Transplantation
10.Essentials of Chronic Kidney Disease
Notifications more
NotificationsNotify me of updates to Neutrophil Gelatinase-Associated Lipocalin: from Laboratory to Clinical Utility
Tell A Friend
 
Tell someone you know about this product.
Neutrophil Gelatinase-Associated Lipocalin: from Laboratory to Clinical Utility
Retail Price: $205.00
10% Online Discount
You Pay:

$184.50
Editors: Mina Hur and Salvatore Di Somma (Dept. of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea; Dept. of Medical-Surgery Sciences and Translational Medicine, University La Sapienza Rome, Rome, Italy)
Book Description:
Acute kidney injury (AKI), defined as an abrupt decrease in renal function over a period of hours to days, is a common complication among hospitalized patients with different acute diseases. Its incidence has been increasing in recent years and is reported to be very high especially in the acute settings. Since clinical signs and symptoms of acute renal damage are not specific, it is difficult to promptly distinguish AKI at the time of patient presentation. Currently the diagnosis of AKI requires serial assessment of laboratory tests over a period of several days, and is based mainly on the evaluation of serum creatinine (sCr) and decrease in urine output as supported by Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (RIFLE) criteria, Acute Kidney Injury Network (AKIN) criteria, and the recent Kidney Disease: Improving Global Outcomes (KDIGO) practice guidelines for AKI. Such a need for repeated sCr evaluations and monitoring of urinary output for too long time after admission could therefore result in a diagnostic delay. With delays in diagnosis, clinicians miss opportunities to start appropriate treatment to minimize damage, and patients incur more severe AKI with subsequent greater risk of developing progression of renal damage leading to chronic kidney disease (CKD), dialysis and increased risk of severe cardiovascular diseases and death.

As a consequence, the use of biomarkers of acute kidney damage could be of great utility in order to distinguish AKI from volume responsive renal dysfunction, CKD, or normal renal function. Furthermore, these biomarkers could contribute to the diagnosis of AKI by identifying a subgroup with ‘subclinical AKI’ where there may be an injury even in the absence of sCr increase, thus leading to an earlier risk stratification of patients with prompt and specific treatment strategies. An earlier detection of acute renal damage promptly mirrored through AKI biomarkers could lead to an appropriate treatment with the aim to stop the progression of ongoing irreversible renal damage.

An ideal biomarker for AKI should distinguish prerenal AKI from apoptotic & necrotic tubular cell damage; be specific for kidney tissue lesion; be upregulated shortly after an injury in the organ tissue; predict outcome; act as surrogate end point useful for clinical interventional approaches; and be independent of glomerular filtration rate level. Among the emerging novel biomarkers of AKI, neutrophil gelatinase-associated lipocalin (NGAL) has got growing attention as the most reliable and promising AKI marker, and its clinical usefulness has been investigated in a variety of clinical settings and different acute diseases.

This specialized book is focused on lipocalin including NGAL and covers the broad aspects of this biomarker from laboratory to clinical utility. This book consists of three parts: basic information on lipocalin; laboratory consideration on NGAL; and clinical utility of NGAL. This book is unique in that it is the first comprehensive book, which provides summarized and up-to-date knowledge on NGAL and its related topics to the researchers and clinicians who are interested in this biomarker.

In particular, this book was conceived reflecting the spirit of GREAT network, an Academic Research Organization, operating as an International Network between experts in the management of acute diseases. Written and reviewed by the experts in each related filed, this book would be a valuable and practical reading for the researchers and clinicians involved in laboratory medicine, emergency medicine, cardiology, nephrology, internal medicine, geriatric and intensive care, etc. (Imprint: Nova Biomedical)

Table of Contents:
Preface pp.vii-viii

Chapter 1. Lipocalin: Sequence and Structure Relationships
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.1-10

Chapter 2. Common Molecular-Recognition Properties
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.11-18

Chapter 3. Biochemistry and Pathophysiology of NGAL
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.19-30

Chapter 4. Function of Lipocalin
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.31-40

Chapter 5. Lipocalin: Cell Regulation, Cancer Cell Interaction
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.41-48

Chapter 6. Urinary versus Plasma NGAL
(Giorgio Zampini, Benedetta De Berardinis and Salvatore Di Somma, Department of Emergency Medicine, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza Rome, Sant’Andrea Hospital, Italy)pp.49-54

Chapter 7. History of NGAL Assays
(Patrizia Cardelli and Laura Magrini, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.55-60

Chapter 8. Diagnostic Performances of NGAL Assays
(Patrizia Cardelli and Laura Magrini, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.61-66

Chapter 9. Stability and Half-Life: In Vitro, Preanalytical Factors
(Patrizia Cardelli, Department of Molecular and Clinical Medicine, Sant’Andrea Hospital, Sapienza University, School of Medicine, Rome, Italy)pp.67-72

Chapter 10. Reference Ranges and Cut-Off Values for the NGAL Assay
(Yeo-Min Yun, Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea)pp.73-86

Chapter 11. NGAL vs. Creatinine
(Hee-Won Moon and Mina Hur, Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea)pp.87-100

Chapter 12. Comparison of NGAL with other New Biomarkers for Kidney Disease
(Francesco Vetrone, Benedetta De Berardinis, and Salvatore Di Somma, Department of Medical-Surgery Sciences and Translational Medicine, Sapienza University, and Emergency Medicine, Sant’Andrea Hospital, Rome, Italy)pp.101-112

Chapter 13. NGAL: A Marker for Acute Kidney Injury
(W. Frank Peacock, Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital, Houston, Texas, USA)pp.113-118

Chapter 14. NGAL In Acute Heart Failure Patients
(Fatima Iqbal, Hermineh Aramin, Minal V. Patel, Matt Kawahara, Sumita Sharma and Alan S. Maisel, Veterans Affairs San Diego Healthcare System, San Diego, and Department of Medicine, University of California at San Diego, La Jolla, California, USA)pp.119-132

Chapter 15. NGAL in Septic Patients
(Laura Magrini, Benedetta De Berardinis, Mina Hur and Salvatore Di Somma, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza Rome, Emergency Department Emergency Medicine Sant’Andrea Hospital, Rome, Italy and others)pp.133-138

Chapter 16. NGAL in Contrast-Induced Nephropathy
(Benedetta De Berardinis, Laura Magrini and Salvatore Di Somma, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza, and Emergency Department, Emergency Medicine, Sant’Andrea Hospital, Rome, Italy)pp.139-150

Chapter 17. NGAL In Hypovolemic Patients
(Francesca Orsini, Laura Magrini, Alan Maisel and Salvatore Di Somma, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza, and Emergency Department, Emergency Medicine, Sant’Andrea Hospital, Rome, Italy and others)pp.151-160

Chapter 18. NGAL In Children and Newborns
(Laura Magrini, Benedetta De Berardinis, and Salvatore Di Somma, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza, and Emergency Department, Emergency Medicine, Sant’Andrea Hospital, Rome, Italy)pp.161-168

Chapter 19. NGAL As Marker for Prognosis of Acute Kidney Injury
(Michael Haase and Anja Haase-Fielitz, Department of Nephrology, Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Germany)pp.169-182

Chapter 20. Multi-Markers Approach Including NGAL and other Biomarkers
(Salvatore Di Somma, Laura Magrini, Benedetta De Berardinis and Mina Hur, Department of Medical-Surgery Sciences and Translational Medicine, University Sapienza, and Emergency Department, Emergency Medicine, Sant’Andrea Hospital, Rome, Italy)pp.183-190

Index pp.191-197

   Series:
      Renal and Urologic Disorders
   Binding: Hardcover
   Pub. Date: 2014 - 3rd Quarter
   Pages: pp.105 6x9 - (NBC-C)
   ISBN: 978-1-63117-984-6
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.The New Science of Curiosity
03.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
04.Chronic Disease and Disability: The Pediatric Lung
05.Fruit and Vegetable Consumption and Health: New Research
06.Future Perspectives on Nigella sativa: Characterization and Pharmacological Properties
07.Wine and Winemaking: The Value and Efficiency
08.Impacts and Challenges in Oil Palm Cultivation and Downstream Applications of Biomass
09.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2
10.The Life and Times of the World's Most Famous Mathematicians
11.Innovation Processes in the Social Space of the Organization
12.High-Strength Steels: New Trends in Production and Applications

Nova Science Publishers
© Copyright 2004 - 2018

Neutrophil Gelatinase-Associated Lipocalin: from Laboratory to Clinical Utility